| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Michael A. Curran | Q39370315 |
| Todd Bartkowiak | Q55459016 | ||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers | Q28213241 | ||
| 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity | Q28217502 | ||
| Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B | Q28261699 | ||
| Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin | Q28537820 | ||
| Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies | Q28656460 | ||
| Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production | Q28740530 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. | Q30573747 | ||
| Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice | Q33374623 | ||
| Clinical effects and toxicity of interleukin-2 in patients with cancer | Q33452555 | ||
| Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration | Q33575781 | ||
| A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | Q33586493 | ||
| Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. | Q33730717 | ||
| Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation | Q33756678 | ||
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines | Q33857971 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy | Q33887448 | ||
| 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms | Q80087479 | ||
| Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival | Q80530765 | ||
| Role of endogenous 4-1BB in the development of systemic lupus erythematosus | Q80562640 | ||
| 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation | Q80633537 | ||
| Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody | Q81229532 | ||
| Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy | Q81310257 | ||
| Absence of 4 1BB gene function exacerbates lacrimal gland inflammation in autoimmune-prone MRL-Faslpr mice | Q81358090 | ||
| Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice | Q81692257 | ||
| CD137 promotes proliferation and survival of human B cells | Q82234590 | ||
| Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion | Q82349360 | ||
| Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies | Q83365600 | ||
| Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15 | Q84616024 | ||
| Implications of immunological surveillance for cancer therapy | Q93698140 | ||
| Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model | Q33889603 | ||
| SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. | Q34065110 | ||
| Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells | Q34258584 | ||
| SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ | Q34369526 | ||
| Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein | Q34403700 | ||
| 4-1BB signaling breaks the tolerance of maternal CD8+ T cells that are reactive with alloantigens | Q34429170 | ||
| Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. | Q34485933 | ||
| Exposure of a distinct PDCA-1+ (CD317) B cell population to agonistic anti-4-1BB (CD137) inhibits T and B cell responses both in vitro and in vivo | Q34491239 | ||
| 4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae | Q34532195 | ||
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors | Q34789146 | ||
| 4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells | Q34854412 | ||
| CD137 facilitates the resolution of acute DSS-induced colonic inflammation in mice | Q34984338 | ||
| CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice | Q34997923 | ||
| CD137-CD137L interaction regulates atherosclerosis via cyclophilin A in apolipoprotein E-deficient mice | Q35092856 | ||
| CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation | Q35228053 | ||
| Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders | Q35561102 | ||
| Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells | Q35627064 | ||
| Hu.4-1BB-Fc fusion protein inhibits allergic inflammation and airway hyperresponsiveness in a murine model of asthma | Q35649268 | ||
| Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer | Q35726637 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines | Q35781892 | ||
| Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells | Q35803631 | ||
| Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement | Q35883004 | ||
| CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results | Q35953372 | ||
| Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent | Q35987596 | ||
| Effects of 4-1BB signaling on the biological function of murine dendritic cells | Q35995857 | ||
| Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer | Q36174218 | ||
| Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. | Q36183600 | ||
| CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. | Q36204132 | ||
| Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. | Q36220613 | ||
| 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses | Q36380273 | ||
| Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens | Q36382421 | ||
| Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner | Q36384615 | ||
| Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb | Q38758452 | ||
| Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. | Q38924275 | ||
| T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. | Q39149430 | ||
| Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model | Q39155565 | ||
| Gene silencing of 4-1BB by RNA interference inhibits acute rejection in rats with liver transplantation | Q39181872 | ||
| Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. | Q39233955 | ||
| Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer | Q39399821 | ||
| Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal | Q39542600 | ||
| Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. | Q39602916 | ||
| Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma | Q39690697 | ||
| Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ | Q39723178 | ||
| Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. | Q39724400 | ||
| In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. | Q39815528 | ||
| 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo | Q39924661 | ||
| ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo | Q39975642 | ||
| Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. | Q40092180 | ||
| Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo | Q40166130 | ||
| Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes | Q40395443 | ||
| Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes | Q40401659 | ||
| The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma | Q40405897 | ||
| Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation | Q40569714 | ||
| Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. | Q40571610 | ||
| Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 | ||
| NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells | Q40653400 | ||
| Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. | Q40753339 | ||
| Activation of c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-stimulatory molecule. | Q40867745 | ||
| Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model | Q40875572 | ||
| Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase | Q41822506 | ||
| Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function | Q42126236 | ||
| 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy | Q42226054 | ||
| TRAF1 phosphorylation on Serine 139 modulates NF-κB activity downstream of 4-1BB in T cells | Q42520225 | ||
| Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. | Q42799001 | ||
| Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model | Q42834371 | ||
| 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection | Q42957089 | ||
| Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus | Q42992104 | ||
| Unified immune modulation by 4-1BB triggering leads to diverse effects on disease progression in vivo | Q43038028 | ||
| The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy | Q43107407 | ||
| CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion | Q43248975 | ||
| Leukocyte-specific protein 1 links TNF receptor-associated factor 1 to survival signaling downstream of 4-1BB in T cells | Q43560331 | ||
| Immune responses in 4-1BB (CD137)-deficient mice | Q44002226 | ||
| GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology | Q44082240 | ||
| 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. | Q44187638 | ||
| The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses | Q44436557 | ||
| Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index | Q44705970 | ||
| Immunological Surveillance in Neoplasia | Q44862902 | ||
| 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells | Q45054662 | ||
| 4-1BB-mediated immunotherapy of rheumatoid arthritis. | Q45078356 | ||
| Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes | Q45256157 | ||
| Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice | Q45422309 | ||
| Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand | Q45618074 | ||
| Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer | Q45790670 | ||
| Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation | Q45869327 | ||
| NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation | Q45873342 | ||
| The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer | Q45879865 | ||
| T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer | Q45886588 | ||
| Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. | Q45988504 | ||
| Phase I/II study of ipilimumab for patients with metastatic melanoma | Q46087025 | ||
| Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease | Q46606532 | ||
| Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice | Q46686977 | ||
| High expression of OX40 (CD134) and 4-1BB (CD137) molecules on CD4(+)CD25(high) cells in children with type 1 diabetes. | Q46723432 | ||
| Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites | Q46756971 | ||
| Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection | Q47188682 | ||
| 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells | Q47298606 | ||
| Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2. | Q47622867 | ||
| Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. | Q36456487 | ||
| 4-1BB/4-1BBL interaction promotes obesity-induced adipose inflammation by triggering bidirectional inflammatory signaling in adipocytes/macrophages. | Q36500294 | ||
| Analysis of CD137 and CD137L expression in human primary tumor tissues | Q36609301 | ||
| CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice | Q36697649 | ||
| Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin | Q36750028 | ||
| Clinical targeting of the TNF and TNFR superfamilies | Q36762882 | ||
| Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies | Q36787500 | ||
| Immune regulation and control of regulatory T cells by OX40 and 4-1BB | Q36794126 | ||
| Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance | Q36845790 | ||
| Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events | Q36900721 | ||
| Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity | Q36906616 | ||
| Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. | Q36922616 | ||
| Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model | Q37040400 | ||
| IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo | Q37159129 | ||
| 4-1BB functions as a survival factor in dendritic cells | Q37189819 | ||
| Stimulation of the molecule 4-1BB enhances host defense against Listeria monocytogenes infection in mice by inducing rapid infiltration and activation of neutrophils and monocytes | Q37191323 | ||
| Hypercostimulation through 4-1BB distorts homeostasis of immune cells | Q37267938 | ||
| Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). | Q37322945 | ||
| Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer | Q37365673 | ||
| Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer | Q37368087 | ||
| Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors | Q37370587 | ||
| Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion | Q37396078 | ||
| Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity | Q37410596 | ||
| Blockade of 4-1BB and 4-1BBL interaction reduces obesity-induced skeletal muscle inflammation. | Q37433264 | ||
| 4-1BB signaling beyond T cells | Q37728213 | ||
| Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy | Q37728543 | ||
| Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies | Q37809159 | ||
| The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses | Q38073762 | ||
| The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy | Q38081999 | ||
| 4-1BB chimeric antigen receptors | Q38199349 | ||
| Immune checkpoint combinations from mouse to man. | Q38306150 | ||
| Use of oligonucleotide aptamer ligands to modulate the function of immune receptors | Q38317332 | ||
| Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. | Q38332777 | ||
| Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors | Q47874586 | ||
| Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells | Q47906614 | ||
| Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo | Q48020828 | ||
| Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. | Q48932261 | ||
| 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function | Q48961590 | ||
| 4-1BB signal stimulates the activation, expansion, and effector functions of γδ T cells in mice and humans. | Q51022113 | ||
| Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. | Q51738252 | ||
| Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. | Q51842476 | ||
| 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. | Q51996548 | ||
| Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells | Q52004403 | ||
| A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. | Q52886049 | ||
| CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. | Q53340266 | ||
| The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. | Q53542645 | ||
| Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. | Q53588594 | ||
| 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. | Q53636905 | ||
| Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. | Q53653549 | ||
| Enhanced CD4 T cell responsiveness in the absence of 4-1BB. | Q53675000 | ||
| NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. | Q54109907 | ||
| The effect of CD137-CD137 ligand interaction on phospholipase C signaling pathway in human endothelial cells. | Q54406690 | ||
| CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. | Q54567425 | ||
| Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity | Q56902023 | ||
| Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death | Q56908523 | ||
| CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells | Q59415961 | ||
| The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy | Q59415963 | ||
| Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease | Q64375577 | ||
| Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment | Q64377217 | ||
| Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease | Q64379651 | ||
| High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings | Q68809659 | ||
| CD137‐Mediated T Cell Co‐Stimulation Terminates Existing Autoimmune Disease in SLE‐Prone NZB/NZW F1 Mice | Q73343916 | ||
| Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors | Q73400031 | ||
| Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy | Q73400790 | ||
| CD137 expression in tumor vessel walls. High correlation with malignant tumors | Q73731098 | ||
| Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma | Q74075820 | ||
| Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway | Q74442131 | ||
| Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses | Q75355267 | ||
| Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis | Q77522472 | ||
| Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes | Q78596416 | ||
| 4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes | Q79120463 | ||
| Enhanced osteoclastogenesis in 4-1BB-deficient mice caused by reduced interleukin-10 | Q79141933 | ||
| Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment | Q79342882 | ||
| Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes | Q79456112 | ||
| Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation | Q79834578 | ||
| Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling | Q79912637 | ||
| Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice | Q80002719 | ||
| 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation | Q80050424 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 117 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity | |
| P478 | volume | 5 |
| Q43379703 | 4-1BB (CD137) and radiation therapy: A case report and literature review |
| Q58754498 | 4-1BB Signaling Promotes Alveolar Macrophages-Mediated Pro-Fibrotic Responses and Crystalline Silica-Induced Pulmonary Fibrosis in Mice |
| Q28079622 | 4-1BB agonism: adding the accelerator to cancer immunotherapy |
| Q87981825 | 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses |
| Q91632541 | A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells |
| Q56889692 | A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity |
| Q59136671 | A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity |
| Q42378925 | A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members |
| Q50187435 | Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. |
| Q52347485 | Aptamer Therapeutics in Cancer: Current and Future. |
| Q55036897 | Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. |
| Q26740303 | Aptamers: A Feasible Technology in Cancer Immunotherapy |
| Q64886488 | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. |
| Q59800859 | CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs |
| Q64254749 | Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma |
| Q40457683 | Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. |
| Q92718021 | Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model |
| Q47595753 | Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q38852256 | Combinatorial approach to cancer immunotherapy: strength in numbers |
| Q89576428 | Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma |
| Q88547220 | Crystal structure of the human 4-1BB/4-1BBL complex |
| Q39330984 | Delivering safer immunotherapies for cancer |
| Q58700606 | Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9 |
| Q90245083 | Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity |
| Q42047687 | Editorial: Advances in Combination Tumor Immunotherapy |
| Q88549071 | Emerging Systemic Therapies for Colorectal Cancer |
| Q47259954 | Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy |
| Q41192295 | Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands |
| Q26775578 | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect |
| Q38899873 | Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer |
| Q52581741 | Immune checkpoint pathways in non-small cell lung cancer. |
| Q56889817 | Immuno-Oncology: Emerging Targets and Combination Therapies |
| Q38711163 | Immunotherapy for advanced melanoma: future directions. |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q89601739 | In situ genetic engineering of tumors for long-lasting and systemic immunotherapy |
| Q92710342 | Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor |
| Q47986213 | Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives |
| Q54734909 | Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. |
| Q26741392 | NK Cell Subtypes as Regulators of Autoimmune Liver Disease |
| Q38676458 | NK cells and cancer: you can teach innate cells new tricks. |
| Q46527001 | Next generation antibody drugs: pursuit of the 'high-hanging fruit'. |
| Q90353818 | OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer |
| Q64052040 | Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity |
| Q42253745 | PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. |
| Q57079914 | Polycationic carbosilane dendrimer decreases angiogenesis and tumor-associated macrophages in tumor-bearing mice |
| Q38806070 | Programming the immune checkpoint to treat hematologic malignancies. |
| Q46450905 | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. |
| Q91591099 | Regulation of regulatory T cells in cancer |
| Q95832157 | Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells |
| Q58586476 | Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab |
| Q64066845 | Switching on the green light for chimeric antigen receptor T-cell therapy |
| Q36940326 | The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses |
| Q38775177 | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy |
| Q38666253 | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. |
| Q38780472 | The potential roles of dopamine in malignant glioma |
| Q56891562 | The promise and challenges of immune agonist antibody development in cancer |
| Q55386131 | Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. |
| Q55107050 | Tumor immunotherapy: New aspects of natural killer cells. |
| Q55454917 | Update on the Treatment of Metastatic Urothelial Carcinoma. |
Search more.